UBS Asset Management Americas Inc. Has $639,000 Position in Radius Health, Inc. (RDUS)

UBS Asset Management Americas Inc. boosted its holdings in Radius Health, Inc. (NASDAQ:RDUS) by 72.3% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,126 shares of the biopharmaceutical company’s stock after acquiring an additional 5,926 shares during the period. UBS Asset Management Americas Inc.’s holdings in Radius Health were worth $639,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Envestnet Asset Management Inc. boosted its stake in shares of Radius Health by 1.1% during the 1st quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after purchasing an additional 46 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Radius Health by 3.1% during the 1st quarter. Principal Financial Group Inc. now owns 5,970 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 180 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Radius Health by 27.7% during the 2nd quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after purchasing an additional 690 shares during the last quarter. American International Group Inc. boosted its stake in shares of Radius Health by 7.1% during the 1st quarter. American International Group Inc. now owns 19,430 shares of the biopharmaceutical company’s stock worth $751,000 after purchasing an additional 1,284 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Radius Health by 22.9% during the 2nd quarter. SG Americas Securities LLC now owns 8,936 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 1,664 shares during the last quarter.

WARNING: This article was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/11/11/ubs-asset-management-americas-inc-has-639000-position-in-radius-health-inc-rdus.html.

Radius Health, Inc. (RDUS) traded down $0.30 during trading on Friday, reaching $28.10. 1,288,900 shares of the company’s stock were exchanged, compared to its average volume of 961,724. Radius Health, Inc. has a 1 year low of $27.16 and a 1 year high of $55.97. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79.

Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same period last year, the business posted ($1.07) earnings per share. analysts anticipate that Radius Health, Inc. will post -5.4 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on RDUS shares. Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the stock a “buy” rating in a research report on Monday, July 17th. Cantor Fitzgerald set a $65.00 price target on shares of Radius Health and gave the company a “buy” rating in a report on Monday, July 17th. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Jefferies Group LLC restated a “hold” rating and issued a $38.00 price target (up previously from $34.00) on shares of Radius Health in a report on Wednesday, August 9th. Finally, BidaskClub lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $51.00.

In related news, major shareholder Growth N. V. Biotech acquired 50,000 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were purchased at an average price of $36.75 per share, for a total transaction of $1,837,500.00. Following the acquisition, the insider now owns 5,298,799 shares in the company, valued at $194,730,863.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jesper Hoiland acquired 6,800 shares of the business’s stock in a transaction on Tuesday, November 7th. The shares were bought at an average price of $29.04 per share, for a total transaction of $197,472.00. Following the acquisition, the insider now owns 12,900 shares in the company, valued at approximately $374,616. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 425,900 shares of company stock worth $14,380,354. 15.00% of the stock is owned by company insiders.

Radius Health Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply